MedTrace Logo

Redo AF Sub Study (of the Pure EP 2.0 Main Study)

NCT04964440 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2022-02-11

No results posted yet for this study

Summary

This study is a sub study of the Pure EP 2.0 trial. In a redo atrial fibrillation population, this study is designed to collect pulmonary vein signals pre and post ablation therapy, along with other non-pulmonary vein signals of interest during a redo ablation procedure. These signals are later evaluated for clinical relevance and impact on the procedure.

Conditions

  • Atrial Fibrillation Recurrent

Interventions

DEVICE

Pure-EP

Advanced Signal Acquisition and Processing

Sponsors & Collaborators

  • BioSig Technologies, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-03
Primary Completion
2021-07-20
Completion
2022-01-29
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04964440 on ClinicalTrials.gov